375 14.2 KEY STRATEGIES/RIGHT TO WIN 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET 14.3 REVENUE ANALYSIS, 20202024 14.4 MARKET SHARE ANALYSIS, 2024 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 14.6.5.1 COMPANY FOOTPRINT 14.6.5.2 REGION FOOTPRINT 14.6.5.3 FORMAT FOOTPRINT 14.6.5.4 ROUTE OF ADMINISTRATION FOOTPRINT 14.6.5.5 INDICATION FOOTPRINT 14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 14.7.1 PROGRESSIVE COMPANIES 14.7.2 RESPONSIVE COMPANIES 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 14.7.5.1 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 14.8 COMPANY VALUATION & FINANCIAL METRICS 14.9 BRAND/PRODUCT COMPARISON 14.10 COMPETITIVE SCENARIO 14.10.1 PRODUCT APPROVALS 14.10.4 OTHER DEVELOPMENTS 15 COMPANY PROFILES In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View) 396 15.2.1.1 BUSINESS OVERVIEW 15.2.1.2 PRODUCTS OFFERED 15.2.1.3 RECENT DEVELOPMENTS 15.2.2 ELI LILLY AND COMPANY 15.2.4 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED 15.2.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 15.2.8 SCIWIND BIOSCIENCES CO., LTD
TAR DNA binding protein 43 (TDP-43) is a marker that has been identified as both a pathological and biochemical indicator in ALS (172)
and purification is achieved through a biphasic interaction with one of the molecules (the ligand) immobilized to a surface while its partner (the target) is in a mobile phase as part of a complex mixture
FASEB J 19: 7678, 2005
55 Mind-body therapies such as yoga, meditation, and tai chi may help pain, balance, and quality of life in patients with neuropathy
.png)
